A monoclonal antibody is secreted by a single B lymphocyte clone which can only produce a kind of proprietary antibody against an antigen-determining cluster, and has the characteristics of single biological activity and particular specificity of binding with antigen.
The active sites of monoclonal antibody drugs involve a variety of tumor-related signaling pathways and targets. For example, the most common targets are epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), and epidermal growth factor receptor -2 (her-2 /neu, or egfr-2). Besides, there is a group of targets that are getting a lot of attention called “immune checkpoints”.
After the activation of immune cells that regulate the anti-tumor immune response, a variety of highly expressed receptors on the surface of immune cells bind to the highly expressed ligands on the surface of tumor cells to reduce the strength of the immune response, thus down-regulating the intensity of tumor-related immune response. These immunoregulatory sites are known as immune checkpoints. Currently, the most widely studied immune checkpoints are PD-1, PD-L1, and CTLA-4.
Targetmol provides xnum monoclonal antibody drugs, including the above immune checkpoint inhibitors and other types of targeted antibody inhibitors, for scientific research only.
Cat. No. | Product name | CAS No. | Purity | Chemical Structure |
---|---|---|---|---|
T37535 | Camrelizumab | 1798286-48-2 | 98.6% |
|
Camrelizumab (SHR-1210) is a human IgG4-κ monoclonal antibody with high affinity and directed against PD-1.Camrelizumab binds PD-1 with a binding affinity of up ... | ||||
T9903 | Avelumab | 1537032-82-8 | 98.30% |
|
Avelumab is a fully human IgG1 anti-PD-L1 monoclonal antibody. Avelumab shows potential antibody-dependent cell-mediated cytotoxicity. | ||||
T9915 | Eculizumab | 219685-50-4 | 98.20% |
Eculizumab
|
Eculizumab is a recombinant humanized monoclonal antibody against the complement protein C5 | ||||
T9901 | Adalimumab | 331731-18-1 | 98.00% |
|
Adalimumab (anti-TNF-alpha) is the first fully human recombinant IgG1 monoclonal antibody that specifically targets human TNF-alpha. | ||||
T9909 | Pertuzumab | 380610-27-5 | 98.00% |
Pertuzumab
|
Pertuzumab (anti-HER2) a humanized monoclonal antibody and the first in the class of agents called the HER2 dimerization inhibitors impairs the ability of HER2 t... | ||||
T9924 | Obinutuzumab | 949142-50-1 | 98.00% |
|
Obinutuzumab (Obinutuzumab/afutuzumab) GA101) is a glycoengineered Type II CD20 monoclonal antibody in development for non-Hodgkin lymphoma. | ||||
T12177 | Natalizumab | 189261-10-7 | 98.00% |
|
Natalizumab used for the treatment of relapsing remitting multiple sclerosis and Crohn's disease. | ||||
T9905 | Cetuximab | 205923-56-4 | 98.00% |
|
Cetuximab (C225) is a monoclonal antibody that is an inhibitor of human epidermal growth factor receptor (EGFR) (Kd=0.201 nM). Cetuximab has antitumor activity, ... | ||||
T9907 | Nivolumab | 946414-94-4 | 98% |
|
Nivolumab (anti-PD-1) is a genetically engineered fully human immunoglobulin Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell... | ||||
T76795 | Xentuzumab | 1417158-65-6 | 95.21% |
|
Xentuzumab (BI836845) is a recombinant monoclonal antibody to humanised IGF ligand that inhibits IGF1 and IGF2 growth-promoting signalling and inhibits AKT activ... | ||||
T9902 | Atezolizumab | 1380723-44-3 | 95.10% |
|
Atezolizumab anti-PD-L1) is a fully humanized IgG1 monoclonal antibody that blocks the interaction of PD-L1 with both PD-1 and B7.1 but not the interaction of PD... | ||||
T13666 | Dupilumab | 1190264-60-8 | 95.00% |
|
Dupilumab (REGN-668) is a systemic immunomodulator for AD. Dupilumab is a fully human monoclonal antibody against the alpha subunit of the interleukin-4 receptor... | ||||
T76792 | Sibrotuzumab | 216669-97-5 | 95.00% |
Sibrotuzumab
|
Sibrotuzumab (BIBH 1) is a humanized IgG1 monoclonal antibody targeting Fibroblast Activating Protein (FAP).Sibrotuzumab is used in the study of colorectal cance... | ||||
T76830 | Teneliximab | 299423-37-3 | 95.00% |
Teneliximab
|
Teneliximab (Chi220) is a chimeric monoclonal antibody and a tumor necrosis factor receptor superfamily member 5 (CD40) inhibitor that blocks CD40-CD40L interact... | ||||
T38105 | Ixekizumab | 1143503-69-8 | 95.00% |
|
Ixekizumab (LY2439821) is a humanized IgG4 monoclonal antibody that selectively binds and neutralizes interleukin IL-17A with a Kd value of <3 pM.Ixekizumab bloc... | ||||
T35394 | Sintilimab (anti-PD-1) | 2072873-06-2 | 95% |
Sintilimab (anti-PD-1)
|
Sintilimab (IBI308) is a humanized IgG4 monoclonal antibody with significant anti-tumor activity that restores endogenous anti-tumor T-cell responses by binding ... | ||||
T9912 | Trastuzumab | 180288-69-1 |
|
|
Trastuzumab is a humanized monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab has been clinically used to treat HER... | ||||
T9919 | Alemtuzumab | 216503-57-0 |
Alemtuzumab
|
|
Alemtuzumab is a humanized monoclonal antibody against CD52 an antigen found on the surface of normal and malignant lymphocytes. | ||||
T9913 | Ustekinumab | 815610-63-0 |
|
|
Ustekinumab is an anti-IL-12/IL-23 IgG1κ human monoclonal antibody. | ||||
T9926 | Omalizumab | 242138-07-4 |
|
|
Omalizumab is a recombinant humanized monoclonal antibody against human immunoglobulin E IgE) |